Introduction
Hypercholesterolemia has been unevenly associated with increased risk of Alzheimer's disease dementia (AD) [1] ; conflicting associations might be caused by different mediating effects of age, gender, and APOE haplotypes [2] . When in combination with other cerebrovascular risk factors, midlife hypercholesterolemia is usually associated with earlier AD onset [3] , particularly regarding higher levels of low-density lipoprotein cholesterol (LDL- cholesterol) inducing cortical amyloid-ˇ deposition [4] . Though higher total cholesterol has been correlated with faster cognitive decline in patients with AD who use cholinesterase inhibitors [5] , late life hypercholesterolemia might also slow cognitive decline, possibly due to enhanced cerebral perfusion [6] . Vascular risk scores such as the estimated glomerular filtration rate [7] and the 10-year absolute coronary heart disease risk [8] -which depends upon lower levels of high-density lipoprotein cholesterol (HDLcholesterol) and age-dependent higher total cholesterol, among other measures -have been associated with slower cognitive decline in AD [2] , considering that kidneys, the heart, and the brain are all end-organs of vascular disease.
The apolipoprotein E is involved in the transport of lipid components that contribute to build the myelin sheath [9] , whereas the intramembrane enzymes involved in amyloid-ˇ production from the amyloid precursor protein are likely affected by membrane cholesterol content [9, 10] . The brain has the richest availability of cholesterol in the human body [10] , and uptake of cholesterol from HDL-cholesterol is a major source of its disposal to neurons [4] . APOE haplotypes are the most important risk factors for earlier AD onset [3] , though direct genetic effects over cognitive and functional decline are not typically observed [6] . However, APOE4+ carriers usually have increased total cholesterol and LDLcholesterol [1, 11] , while several other common genetic variants act in concert to regulate phenotypic patterns of lipid profile [12] .
Strengths of evidence for effects of statin therapy over clinical change in AD are usually low and biased [13] . Statins could benefit such patients not only by lowering cholesterol levels, but also by their anti-inflammatory [10] , anti-thrombotic and vasodilatory [14] properties, by stimulating the non-amyloidogenic pathway of the amyloid precursor protein [15] , by stimulating the release of the insulin-degrading enzyme from microglia [16] and by increasing the secretion of neprilysin from astrocytes [17] , thus degrading amyloid-ˇ. Nevertheless, most studies do not take APOE haplotypes into account for their analyses.
In this longitudinal study with patients with AD, our primary aim was to investigate associations of lipid profile variations with yearly changes in cognition, caregiver burden, basic and instrumental functionality according to APOE haplotypes. Secondarily, we assessed effects of lipophilic statins over test score changes in one year according to APOE haplotypes.
Subjects and methods

Participants
In this uncontrolled cohort, consecutive outpatients with lateonset AD according to National Institute on Aging -Alzheimer's Association criteria [18] were prospectively recruited from the Behavioral Neurology Section of Hospital São Paulo, Federal University of São Paulo (UNIFESP), from October 2010 to May 2014 (44 months). Late-onset AD was considered when caregivers reported that dementia started after patients turned 60 years-old [3] , while patients with history of stroke were not included in the study. All patients had a magnetic resonance exam to evaluate either medial parietal or medial, basal or lateral temporal atrophy or, in cases of claustrophobia or use of pacemakers, a computed tomography scan to exclude vascular lesions.
All patients had at least three consultations per year, and were assessed for gender, schooling, body mass index, age at dementia onset, alcohol use, smoking, dyslipidemias, diabetes mellitus, arterial hypertension, use of lipid-lowering drugs, use of cholinesterase inhibitors and/or Memantine, and APOE haplotypes. Information concerning age at dementia onset was determined following a review of medical records, and confirmed after an interview with the caregiver (preferably a family member), who should have frequent visits with the patient. The time of subjective memory complaints or mild cognitive impairment was not taken into account, but rather only the time at dementia onset (when functional decline actually started). Participation of each patient was concluded when follow-up completed one year.
Diagnoses of dyslipidemias [8] and diabetes mellitus [19] were based on the results of blood tests, while the diagnosis of arterial hypertension followed the JNC 7 report [20] . Use of lipid-lowering drugs was monitored all year long, while management of dyslipidemias followed specific guidelines [8] . Essentially, goals of total cholesterol, LDL-cholesterol, HDL-cholesterol, and triglycerides were based on the presence or not of symptomatic ischemic heart disease, coronary heart disease risk equivalents (diabetes mellitus and clinical manifestations of non-coronary forms of atherosclerotic disease), and cardiovascular risk factors in general. Unless the 10-year estimated coronary heart disease risk was higher than 10%, drug therapy was introduced only if non-pharmacological management was unsuccessful after 3 months. For all patients who used lipid-lowering drugs, non-pharmacological recommendations including body weight control, regular physical activity, dietary therapy, and smoking cessation were simultaneously employed [21] , whereas pharmacological therapy would be discontinued in case of side effects. All efforts were directed to control hypercholesterolemia and hypertriglyceridemia for all patients rather than just lowering lipid levels.
Neuropsychiatric assessment
In all consultations, patients were scored for the Mini-Mental State Examination [22] , while caregivers were queried for the Clinical Dementia Rating sum-of-boxes [23] , the Index of Independence in Activities of Daily Living [24], Lawton's Scale for Instrumental Activities of Daily Living [25] , and the Brazilian Version of the Zarit Caregiver Burden Interview [26] . All neuropsychiatric assessments were conducted according to previously published guidelines [27] . All functional and cognitive assessments were conducted on weekdays at morning time, by the same examiner (FFO). For statistics, only the first and the last evaluations were taken into account, the last evaluation one year apart from the first one.
Genotyping procedures
Blood samples were collected from all patients in tubes with ethylenediaminetetraacetic acid 0.1%; thereafter, genomic DNA was extracted from venous blood using a standard salting-out procedure for determination of rs7412 and rs429358 by way of TaqMan ® SNP Genotyping Assays on the Applied Biosystems ® 7500 Fast Real-Time PCR System (Applied Biosystems ® , USA). APOE haplotyping was carried out only after clinical data were collected from all patients, thus keeping the observers blinded to such genetic data.
Outcome measures
The primary outcome measure was the variation in one year of caregiver burden, functional and cognitive test scores (dependent variables) according to variations in total cholesterol, LDL-cholesterol, HDL-cholesterol or triglycerides for APOE4+ carriers and APOE4-carriers separately. In secondary analyses, effects of lipophilic statins over test score changes in one year for APOE4+ carriers and APOE4-carriers were also assessed.
Statistical analysis
One-way analysis of variance with post hoc Tukey's test was employed for comparisons between values of body mass index, total cholesterol, LDL-cholesterol, HDL-cholesterol, triglycerides, and test scores during recruitment and at the end of the follow-up. Simple linear regressions were used for assessment of variations in caregiver burden, functional and cognitive test scores according to variations in total cholesterol, LDL-cholesterol, HDL-cholesterol or triglycerides for APOE4+ carriers or APOE4-carriers separately. The Mann-Whitney test was employed for comparisons of variations in caregiver burden, functional and cognitive test scores according to the use or not of lipophilic statins for APOE4+ carriers or APOE4-carriers separately. Levels of significance from simple linear regressions and the Mann-Whitney test were corrected for false discovery rates to minimize the occurrence of type I errors. The threshold of significance was set at < 0.05.
Ethical considerations
This study is part of the research project 1067/10 (CAAE 0540.0.174.000-10) approved by the Ethics Committee of Hospital São Paulo, Federal University of São Paulo (UNIFESP), in August 2010, and has been performed in accordance with The Code of Ethics of the World Medical Association (Declaration of Helsinki) for experiments involving humans. All invited patients and their legal representatives agreed to participate on the research and signed the Informed Consent Form before the evaluation.
Results
By the end of the recruitment, 217 patients had been included. During follow-up, 14 patients (6.5%) passed away, and 11 patients (5.1%) abandoned the study, resulting in a final sample of 192 patients. Tables 1 and 2 show demographic and clinical results, as well as APOE haplotypes for all patients. APOE4+ haplotypes (4/4, 4/3, 4/2) were detected in 102 patients (53.1%), whereas 90 patients (46.9%) carried APOE4-haplotypes (3/3 and 3/2; 2/2 was not represented in the sample). Overall, 189 patients (98.4%) used either a cholinesterase inhibitor, or Memantine, or both, while all but one of the 144 patients with dyslipidemias received statin therapy with or without Ezetimibe; the only patient who had dyslipidemia but did not receive lipid-lowering therapy during the study had previously presented signs of rhabdomyolysis, after which statin therapy was discontinued. Total cholesterol, LDL-cholesterol, Mini-Mental State Examination scores and functional independence scores were significantly lower at the end of the follow-up, while Clinical Dementia Rating sum-of-boxes scores were higher; however, no significant variations in one year were found for caregiver burden, body mass index, HDL-cholesterol, or triglycerides. Table 3 shows results from simple linear regressions between variations in total cholesterol, LDL-cholesterol, HDL-cholesterol and triglycerides in one year for APOE4+ carriers and respective test score variations. Table 4 shows results from simple linear regressions between variations in total cholesterol, LDL-cholesterol, HDL-cholesterol and triglycerides in one year for APOE4-carriers and respective test score variations. Exclusively for APOE4-carriers, each 1 mg/dl raise in HDL-cholesterol levels led to a fall of 0.051 point in the Index of Independence in Activities of Daily Living, while a trend toward functional benefits was found with raising LDL-cholesterol levels; moreover, effects of lipid profile variations over caregiver burden did not survive multiple correlations. APOE4+ carriers were resistant to any functional or cognitive effects of lipid profile variations.
Associations between variations in test scores in one year and use of lipophilic statin therapy or not for APOE4+ carriers or APOE4-carriers are shown in Table 5 . No significant differences were found regarding the use or not of a lipophilic statin for variations in any test scores, neither for APOE4+ carriers, nor for APOE4-carriers, though a non-significant protective effect of lipophilic statin therapy over Clinical Dementia Rating sum-of-boxes score variations could be witnessed for APOE4-carriers.
Discussion
In this study, we found that APOE4-carriers with AD had functional harm with raised HDL-cholesterol levels, while a trend toward functional benefits was seen with raised LDL-cholesterol levels. While it had previously been hypothesized that APOE4-carriers have cholesterol metabolism dysfunction [28] , APOE4+ carriers were resistant to any functional or cognitive effects of lipid profile variations, probably due to their inefficient neural repair mechanisms [9, 29] .
Considering adults without dementia, earlier studies had reported that hypercholesterolemia is negatively associated with cognitive function only among APOE4+ carriers with cardiovascular disease [30] . APOE4-haplotypes might provide higher availability of lipids to protective mechanisms in the neuronal membranes when cholesterol levels are increasing, thus overcoming their supposed metabolic dysfunction. Even though circulating cholesterol does not cross the blood-brain barrier, it has been hypothesized that its oxidized product 27-hydroxycholesterol reaches the brain and corresponds to such effects, despite the fact that blood-brain barrier disruption in AD might enable the influx of cholesterol to the brain [15] . Inefficient neural repair in APOE4+ carriers might not allow the same protective mechanisms of raised cholesterol levels that happen in APOE4-carriers, though cerebrovascular risk may be increased.
An earlier study [21] showed that caregiver awareness of the need to control cerebrovascular risk is higher when patients have dyslipidemias, and has significant impacts over adherence to dietary therapy and to pharmacological treatment, thus justifying the need of caregiver education regarding control of cerebrovascular risk. The fact that 75.0% of all patients had dyslipidemias in this study, and almost all of them used lipophilic statins (thereby crossing the blood-brain barrier) corroborates the burden of this vascular risk factor in older people [14] . Since only two patients used a hydrophilic statin (Rosuvastatin), and only four used Ezetimibe, we could not specifically assess the effects of such therapies.
Statins lower plasma cholesterol concentrations by blocking cholesterol biosynthesis through the inhibition of 3-hydroxy-3-methylglutaryl-CoA reductase [10] , whereas HMGCR variants reportedly modify risk and age at onset of AD [28] . Cognitively healthy adults have a slower rate of annual worsening in Clinical Dementia Rating sum-of-boxes scores [31] and increased regional cerebral blood flow and vascular reactivity [32] when using statins. Former studies have shown that statins could prevent late-onset AD when used in midlife [14] , slow cognitive decline of patients with AD who have hypercholesterolemia [33] , as well as reduce tau pathology and amyloid deposits and the risk of AD mortality [34] . However, one pilot study with a small sample of patients with AD and mixed dementia found an improvement in Mini-Mental State Examination scores with discontinuation of statins and worsening with rechallenge, following total cholesterol decrease and further increase [35] . Some intraclass differences for patients with mild to moderate AD have been reported, though, with cognitive benefits and aggressive cholesterol reductions following high-dose Atorvastatin treatment at six months up to one year [36] , but not with dose escalation of Simvastatin even after eighteen months [37] . No significant functional or cognitive impacts were seen concerning statin therapy after one year in our sample, even though a nonsignificant protective effect of lipophilic statin therapy over Clinical Dementia Rating sum-of-boxes score variations could be observed for APOE4-carriers. It had previously been reported that statins have more protective effects over the white matter microstructure for APOE4-carriers without dementia than for APOE4+ carriers [29] . Differently from earlier studies, it should be noted that only patients with dyslipidemias received statin therapy in our sample.
Major strengths of this study include the longitudinal design and the fact that assessments of functional and cognitive decline, dyslipidemias, diabetes mellitus and arterial hypertension were well documented all along the follow-up, thus avoiding a classification bias that could have resulted from self-reported cerebrovascular risk factors. Except for caregiver burden, all other test scores were significantly different after one year, thus confirming that this length of follow-up was proper for most measures. Limitations of this study include the fact that it was conducted in a single center with no randomization. Also, it is unknown whether the effects of lipophilic statins would be either dose-dependent or more significant when starting treatment or at any time during therapy, due to the fact that many patients were already under treatment when they were included in the study. We tried to minimize these limitations by keeping observers blinded to genetic data during the evaluations, whereas the fact that almost all patients were treated with a cholinesterase inhibitor and/or Memantine helped avoid biases of variations in cognitive enhancement therapy [38] .
Conclusions
In conclusion, APOE4-carriers with AD had functional harm with raising HDL-cholesterol levels, whereas a trend toward functional benefits was seen with raised LDL-cholesterol levels in one year. Lipophilic statins had non-significant protective effects over global functional and cognitive score variations only for APOE4-carriers. While APOE haplotypes seem to influence the protective effects of lipid profile variations for patients with AD, there is insufficient evidence to propose lipid-lowering drugs as treatment for AD at present. Multicenter trials might be required to confirm the role of statins and lipid profile variations over clinical change in AD.
